Beta Drugs Ltd, a company in the Pharmaceuticals industry, reported revenue of ₹137 crore and net profit of ₹19 crore for the September 2026 quarter.
Beta Drugs Ltd (NSE: BETA) closed at ₹1,655.40 on 20 Nov 2026, up 1.4% over the past year. Its market capitalisation is ₹1,841 crore and it trades at 35.5 times earnings.
Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.